Janus Henderson Group
MREO

Janus Henderson Group’s Mereo BioPharma MREO Stock Holding History

Janus Henderson Group’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,290,130
Closed -$33.6M – 2445
2025
Q3 		$33.6M Sell
16,290,130
-1,398,462
-8% -$2.58M 0.02% 495
2025
Q2 		$48.1M Sell
17,688,592
-5,046,529
-22% -$12.2M 0.02% 395
2025
Q1 		$52.4M Buy
22,735,121
+5,612,558
+33% +$15.9M 0.03% 368
2024
Q4 		$59.8M Buy
17,122,563
+4,776,697
+39% +$18.8M 0.03% 347
2024
Q3 		$50.9M Buy
12,345,866
+4,464,984
+57% +$18.5M 0.03% 384
2024
Q2 		$28.4M Buy
7,880,882
+2,760,309
+54% +$8.94M 0.02% 502
2024
Q1 		$16.9M Buy
+5,120,573
New +$17.3M 0.01% 587
2021
Q1 		– Sell
-1,124,678
Closed -$4M – 1604
2020
Q4 		$4M Buy
+1,124,678
New +$2.82M ﹤0.01% 1004

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Janus Henderson Group's MREO Position: Q4 2025 in Review

Janus Henderson Group sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 16,290,130 shares — an estimated $33.6M sold.

Janus Henderson Group first reported a position in MREO in Q4 2020 and held it in 8 quarters. The position peaked at $59.8M in Q4 2024. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Janus Henderson Group reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Janus Henderson Group sold 16,290,130 Mereo BioPharma shares in Q4 2025, an estimated $33.6M.
  • Janus Henderson Group first reported a position in Mereo BioPharma in Q4 2020 and held it in 8 quarters.
  • Janus Henderson Group's Mereo BioPharma position peaked at $59.8M in Q4 2024.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Janus Henderson Group's 13F filing for Q4 2025, filed 17 Feb 2026.